<DOC>
	<DOC>NCT02238184</DOC>
	<brief_summary>To obtain further information on the prescribing pattern and therapeutic long term value in patients suffering from moderate or severs Chronic Obstructive Pulmonary Disease under conditions of daily practice</brief_summary>
	<brief_title>Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Cholinergic Antagonists</mesh_term>
	<mesh_term>Oxitropium</mesh_term>
	<criteria>Patients of both genders older than 40 years, who suffer from moderate or severe Chronic Obstructive Pulmonary Disease Only patients who showed following diagnosis parameters were to be considered for inclusion FEV1 (Forced expiratory volume in 1 second) and FEV1/VC (vital capacity) &lt;70% Reversibility FEV1 &lt;12% in the last 6 months Smoker or Exsmoker (&gt;10 Pack years) Asthma to be excluded â€¢ Contraindications listed in the Instructions for Use/Summary of Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>